Established Cardiovascular Disease: What Counts as Treatment Failure

What "established cardiovascular disease" means here

Established cardiovascular disease (CVD) is a category, not a single diagnosis. It covers a prior myocardial infarction, an ischemic stroke or transient ischemic attack, peripheral arterial disease, or symptomatic coronary artery disease confirmed by angiography or functional testing. Cardiology and lipid guidelines classify these patients as very-high risk and set more aggressive treatment targets for them than for someone without a prior event. This is distinct from primary prevention, where risk-factor thresholds for starting or intensifying therapy are generally less strict. A person newly diagnosed with hypertension and no prior event is managed differently than someone three years past a heart attack with the same blood pressure reading, and the word "failure" only applies meaningfully once a patient has crossed into the established-disease category.

The core answer, stated plainly: treatment failure in established CVD means a patient already on guideline-directed medical therapy still has LDL-C above the guideline target, experiences a new atherosclerotic event, cannot tolerate the medications needed to reach that target, or shows heart failure that does not stabilize despite maximally tolerated foundational drugs. These are guideline-derived thresholds from bodies such as the ACC/AHA and ESC/EAS, not outcomes from any single trial, and they apply specifically to patients with a documented prior event rather than to people being treated for risk factors alone. Which threshold has been crossed determines which add-on therapy has trial support, whether that is ezetimibe, a PCSK9 inhibitor, an SGLT2 inhibitor, or a GLP-1 receptor agonist.

Cardiovascular disease remains a leading cause of death and a major driver of hospitalization in the United States, and coronary artery disease alone affects a large share of American adults, according to CDC data (2024). [1] That scale is part of why guideline bodies have worked to define concrete failure thresholds rather than leaving escalation to clinical impression alone.

Four ways treatment can be said to have failed

Guideline bodies do not use one universal phrase for "treatment failure," but their recommendations converge on four distinct failure patterns: residual lipid risk, a recurrent atherosclerotic event, drug intolerance, and ongoing heart failure despite maximal therapy.

1. LDL-C stays above target despite optimized statin therapy

Cholesterol guidelines describe high-intensity statin therapy as the foundation of treatment for established CVD, with add-on therapy considered if LDL-C remains at or above target after a period of optimized statin use, typically assessed around three months. If LDL-C is still above target on a statin, ezetimibe is generally the next addition; if it remains above target on statin plus ezetimibe, a PCSK9 inhibitor (evolocumab or alirocumab) is a guideline-supported option in appropriately selected patients. Trials in this space, including IMPROVE-IT (ezetimibe added to a statin after acute coronary syndrome) and FOURIER (evolocumab in established CVD), reported reductions in composite cardiovascular endpoints when these add-on agents were used in patients not at target on statin alone. The exact percentage reductions and confidence intervals from these trials are widely cited but should be checked against the original New England Journal of Medicine publications before being restated as precise figures in patient-facing material, since secondhand citation chains for these numbers are easy to corrupt.

2. A new MI, stroke, or cardiovascular death happens on therapy

A recurrent non-fatal MI, non-fatal stroke, or cardiovascular death while a patient is on guideline-directed therapy is the clearest single signal that current treatment is not sufficient for that patient. Post-MI cohorts followed for several years continue to show a meaningful rate of second events even in contemporary practice, which is one reason guidelines treat "on-treatment recurrence" as an automatic trigger for a full medication review rather than a minor adjustment. That review should reassess statin dose and adherence, antiplatelet regimen, blood pressure control, diabetes management, and weight, because each is an independent and modifiable contributor to residual risk.

If a new event involves chest pain, one-sided weakness, slurred speech, sudden vision loss, or acute shortness of breath, that is an emergency. It needs immediate emergency evaluation, not a scheduled follow-up visit.

3. Statin intolerance after two documented trials

Statin-associated muscle symptoms are reported at varying rates across observational cohorts, and estimates in the literature range widely depending on study design. Guideline definitions of statin intolerance generally require documented failure of at least two different statins, including one trial at the lowest approved dose or with alternate-day dosing, before a patient is labeled intolerant and moved to non-statin therapy as the primary LDL-lowering strategy. A reasonable clinical sequence before reaching that label is: retry the same statin at a lower dose, switch to a different statin, and consider alternate-day dosing for a statin with a longer half-life. Non-statin options at that point include ezetimibe, bempedoic acid, and PCSK9 inhibitors; a large outcomes trial of bempedoic acid in statin-intolerant patients (CLEAR Outcomes) reported a reduction in major cardiovascular events compared with placebo, though again the exact effect size should be verified against the primary publication before being quoted as a fixed number.

4. Heart failure that does not stabilize despite maximal therapy

For patients whose established CVD includes heart failure with reduced ejection fraction, heart failure guidelines describe treatment failure in terms of persistently reduced ejection fraction, persistent New York Heart Association class III or IV symptoms, or repeated hospitalizations for decompensated heart failure despite maximally tolerated therapy with an ACE inhibitor, ARB, or ARNI, a beta-blocker, and a mineralocorticoid receptor antagonist. Trials such as DAPA-HF reported that adding an SGLT2 inhibitor to this foundation further reduced the composite of worsening heart failure or cardiovascular death, which is why SGLT2 inhibitors are now generally considered part of foundational HFrEF therapy rather than a late add-on, subject to individual contraindications and renal function.

Residual risk that LDL-C alone does not capture

LDL-C at target does not mean risk is fully addressed. Several other pathways contribute to residual risk even when cholesterol looks controlled.

Triglycerides and HDL. Elevated triglycerides on statin therapy, in a range many clinicians previously treated as acceptable, are now recognized as a distinct residual-risk signal. The REDUCE-IT trial reported a reduction in major cardiovascular events with icosapent ethyl added to statin therapy in patients with elevated triglycerides, though the specific triglyceride range and effect size reported in that trial should be confirmed against the original publication before being used as an exact prescribing threshold.

Inflammation. Persistent inflammation, often measured by high-sensitivity CRP, has been associated with recurrent events independent of LDL-C in some trial populations, and colchicine has been studied as an anti-inflammatory add-on in stable coronary disease. Separately, observational research in patients with persistent atrial fibrillation and metabolic comorbidities has suggested that epicardial adipose tissue inflammation, assessed by CT attenuation, may differ based on metabolic comorbidity status. That finding is specific to an atrial fibrillation population, not general established CVD, and it supports the plausibility of metabolic-inflammatory pathways contributing to residual risk rather than proving that anti-inflammatory therapy changes outcomes broadly. Whether inflammatory markers should routinely change management in a typical secondary-prevention patient outside a trial protocol remains a matter of clinical judgment rather than settled guideline consensus.

Blood pressure. A systolic blood pressure persistently above the guideline threshold on two or more antihypertensive agents is generally treated as a distinct failure mode requiring adherence confirmation, evaluation for secondary causes, and addition of a third agent from a different class.

Should weight be treated as a cardiovascular treatment-failure signal?

Excess body weight sustains cardiovascular risk through insulin resistance, dyslipidemia, hypertension, and systemic inflammation even when individual risk factors are separately "controlled." The SELECT trial changed how this is discussed clinically. It enrolled adults with established CVD, an elevated BMI, and no diabetes at baseline, and compared weekly subcutaneous semaglutide against placebo on top of standard care. The trial reported a reduction in a composite of cardiovascular death, non-fatal MI, and non-fatal stroke in the semaglutide group. This was among the first trials to show that a weight-management medication reduced hard cardiovascular endpoints in people without diabetes, which is clinically significant regardless of the exact percentage reduction reported, and that exact figure should be verified against the primary NEJM publication before being restated with confidence in clinical materials.

An important nuance from the trial: the reported divergence in cardiovascular events between groups appeared before most of the weight loss had accumulated, which is consistent with (but does not prove) effects on inflammation or vascular biology beyond weight reduction alone. This is a plausible mechanism, not an established one, and readers should not treat it as settled pharmacology.

Semaglutide for cardiovascular risk reduction in this population is an on-label use following FDA review of the SELECT data for a semaglutide product; readers should confirm the current FDA label and indication wording directly, since label language and REMS requirements can change. GLP-1 receptor agonists have known gastrointestinal side effects, contraindications including personal or family history of medullary thyroid carcinoma, and a nontrivial rate of discontinuation in trials due to tolerability. They are not a substitute for lipid, blood pressure, or antiplatelet therapy; they are an addition considered when weight itself looks like an unaddressed risk driver.

Antithrombotic therapy: when has the current regimen stopped working?

Dual antiplatelet therapy after acute coronary syndrome or stent placement is standard for a defined period, generally described in guidelines as roughly six to twelve months, after which many patients move to single antiplatelet therapy. A new MI or acute coronary syndrome occurring on single antiplatelet therapy after that window is a clear antithrombotic failure signal, and trials of extended dual antiplatelet therapy (for example, ticagrelor added to aspirin beyond the standard window) have reported reduced recurrent event rates in selected post-MI populations, at the cost of increased bleeding risk, which is why extension is individualized rather than automatic.

Some patients show high on-treatment platelet reactivity despite clopidogrel. Switching to a more potent P2Y12 inhibitor such as ticagrelor or prasugrel is a described approach to this pharmacologic failure mode in patients undergoing PCI, particularly those with diabetes or a prior stent thrombosis, based on outcomes trials comparing these agents to clopidogrel. Exact trial percentages for these comparisons should be checked against the primary literature before being presented as fixed figures.

A decision framework: is this treatment failure, or something else?

Before escalating therapy, walk through this sequence. It is designed to catch the most common misclassification in secondary prevention: mistaking an adherence or dosing gap for true pharmacologic failure.

Step 0, Rule out the impostor causes first. Before labeling anything a drug failure, check:

• Pharmacy refill history or pill counts. A meaningful gap in days-covered suggests an adherence problem, not a drug problem.
• Whether the patient is actually on the guideline-recommended intensity of the drug, or was quietly stepped down after an undocumented side-effect conversation.
• Whether blood pressure or lipid readings were taken under conditions that could distort them (white-coat effect, non-fasting sample where fasting was intended, recent acute illness).

If any of these are unresolved, address them before concluding the medication itself has failed.

Step 1, Which of the four failure modes applies?

Step 2, Is weight an unaddressed risk driver? If BMI remains elevated after a genuine attempt at structured lifestyle intervention, and the patient has established CVD, this is a reasonable point to discuss a GLP-1 receptor agonist with trial support (SELECT), independent of whether lipid and blood pressure numbers happen to be at goal. This is a site-level judgment call about when "structured lifestyle intervention" has been adequately tried, not a fixed guideline rule with a universal timeline.

Step 3, Decide: adjust, add, or refer.

• Adjust: dose or adherence issue found in Step 0. Fix that first and recheck before adding anything.
• Add: a clear guideline threshold from Step 1 has been crossed and adherence is confirmed. Add the indicated agent.
• Refer: familial hypercholesterolemia suspected (very high LDL-C or strong family history), blood pressure uncontrolled on three agents including a diuretic, recurrent acute coronary syndrome despite optimized therapy, or ejection fraction that remains low despite four-drug heart failure therapy. These situations generally exceed routine primary-care management and warrant a lipid specialist, hypertension specialist, interventional cardiologist, or heart failure/device specialist as appropriate.

What is established, what is plausible, and what is not settled

Established: guideline bodies define specific LDL-C, recurrence, intolerance, and heart failure thresholds for escalating therapy in patients with a documented prior atherosclerotic event; multiple outcome trials support add-on therapies (ezetimibe, PCSK9 inhibitors, SGLT2 inhibitors, icosapent ethyl in appropriate patients) at those thresholds; SELECT established that a GLP-1 receptor agonist can reduce major cardiovascular events in a population with established CVD, elevated BMI, and no diabetes.

Plausible but not proven: that early cardiovascular benefit from GLP-1 receptor agonists is driven substantially by anti-inflammatory or vascular mechanisms independent of weight loss; that hs-CRP-guided anti-inflammatory therapy should be routine outside trial-defined populations; that inflammatory findings from atrial fibrillation cohorts generalize to the broader established-CVD population.

Not established here: exact current numeric guideline thresholds, exact trial effect sizes, and current FDA label wording for any named drug should not be treated as fixed without checking the current guideline document or label directly, since these numbers can be updated and secondhand citation chains (including in earlier drafts of pages like this one) are a known failure point.

Adherence gaps look like treatment failure and are not the same thing

One of the most common errors in managing established CVD is labeling a patient pharmacologically refractory when the real problem is nonadherence or underdosing. Survey data from European secondary-prevention cohorts have repeatedly found that a substantial share of coronary patients are not taking statins at guideline-recommended intensity and have not reached LDL-C targets, which suggests that for many patients, the practical gap is a prescribing or adherence gap rather than a true biological non-response. Confirming adherence and correct dosing before escalating therapy is not a delay tactic; it changes what the correct next step actually is.

When to refer instead of escalating in place

• Suspected familial hypercholesterolemia (very high LDL-C, strong family history, or a high clinical score on a validated tool): refer to a lipid specialist.
• Blood pressure uncontrolled on three agents including a diuretic: refer for evaluation of secondary causes such as renal artery stenosis or primary aldosteronism.
• Recurrent acute coronary syndrome within about a year despite optimized antiplatelet and lipid therapy: refer for interventional cardiology reassessment.
• Persistently low ejection fraction despite maximally tolerated four-drug heart failure therapy: refer for evaluation for a defibrillator or resynchronization device per current heart failure guideline recommendations.